It consists of iPSC: HEL115.6-derived islet-like aggregates treated with IFNα for 24 h and submitted to RNA-seq (n=5) and scRNA-seq (n=5). ( Table 1 ). Data repository: RNA-seq: GSE203430 scRNA-seq: GSE203384 Publication: PMID 36103539

It consists of human islets (n=5) treated with IFNγ + IL-1β with or without difluoromethylornithine (DFMO) and submitted to RNA-seq and proteomics analysis ( Table 1 ). DFMO is an inhibitor of ornithine decarboxylase (ODC), an enzyme of the polyamine pathway. Therefore, this treatment was done to...

It consists of sets of EndoC-βH1 cells treated in parallel with IFNα, IFNγ, IL-1β and TNFα for 24 h and submitted to RNA-seq (n=4) ( Table 1 ) Data repository: GSE235683 Publication: PMID 38409439

It consists of paired human islets treated with IFNγ + IL-1β for 48 h and submitted to RNA-seq (n=5), ATAC-seq (n=5), UMI-4C18 (n=2 or 3, depending on the viewpoint), and ChIP-seq for histone H3 lysine 27 acetylation (H3K27Ac) (n=4) ( Table 1 ). Islets across the two studies originated from...

It consists of human islets (n=10, subdivided into 2 batches) treated with IFNγ + IL-1β for 24 h and submitted to proteomics, lipidomics and metabolomics in the same samples ( Table 1 ) Data repositories: Proteomics: PXD009131 Lipidomics: MSV000086174 Metabolomics: https://osf.io/nskdc Publications...

It consists of MIN6 cells (n=3) treated with IFNγ + IL-1β + TNFα with or without DFMO or N1,N11-diethylnorspermine (DENSpm) and submitted to RNA-seq ( Table 1 ). DENSpm is an inhibitor of ornithine decarboxylase (ODC) and polyamine oxidase (PAOX), both enzymes in the polyamine pathway. Therefore...

It consists of MIN6 cells (n=4) treated with IL-1β + IFNγ + TNFα for 24 h post-RNAi targeting ADP-ribosylhydrolase ARH3 (Adprhl2), and submitted to proteomics analysis ( Table 1 ). ARH3 is a hydrolase that keeps cellular ADP-ribosylation levels in check and is regulated by omega-3 FA to protect β...

It consists of human islets treated for 48 h with cytokines (IFNγ, TNFα, and/or IL1β), thapsigargin (TG), brefeldin A (BFA), or DMSO for the control (CTRL) and submitted for single-cell RNA-seq (n=5) and single-nucleus multi-omics sequencing (snMultiomics-seq, n=1) ( Table 1) . In this study...

It consists of β-TC-6 cells treated with IFNγ + IL-1β for 4, 8 or 24 h (n=4) and submitted to enrichment of cysteine-containing peptides (redox), phosphopeptides and acetylated peptides. This enabled the analysis of proteomics, redox cysteine, phosphoproteomics and acetylomics within the same...

It consists of sets of β-TC-3 cells (n=3) treated with IL-1β + IFNγ + TNFα for 24 h with or without ML351 and submitted to RNA-seq ( Table 1 ). ML351 is an inhibitor of 12-lipoxygenase, an enzyme that produces 12-HETE. Therefore, this treatment was done to study whether inhibiting 12-HETE synthesis...

It consists of MIN6 cells (n=4) treated with IL-1β + IFNγ + TNFα and RNAi targeting Poly(ADP)ribosyl polymerase 12 ( Parp12 ) for 24 h and submitted to proteomic analyses ( Table 1 ). PARP12 is an interferon-induced protein known to target viral RNA to stress granules. It has been reported to have...

It consists of human islets (n=6) treated with IFNγ + IL-1β for 24 h and submitted to top-down proteomics ( Table 1 ). Data repository: MSV000097810 Publication: PMID 40977091

It consists of MIN6 cells (n=4) treated with IL-1β + IFNγ + TNFα for 24 h post RNAi targeting 85/88 kDa calcium-independent phospholipase A2 ( Pla2g6 ) and submitted to proteomics analysis ( Table 1 ). Pla2g6 is an enzyme that metabolizes phosphatidylcholine (PCs) into polyunsaturated fatty acids...

It consists of human islets and EndoC-βH1 cells treated with IFNα for 2, 8, or 24 h and submitted to RNA-seq (human islets: n=6 & EndoC-βH1: n=5) and ATAC-seq (n=4). In parallel, a batch of cells (n=4) had proteomics, lipidomics, and metabolomics performed in the same samples ( Table 1 ) Data...

It consists of human islets (n=8) treated with IFNγ + IL-1β for 24 h and submitted to phosphoproteomics ( Table 1 ). Data repository: PXD011857 Publication: PMID 30843680